XimluciⓇ maintained a 7% market share in Europe with ongoing cost reduction efforts, while Lucamzi™ awaits FDA approval and Xdivane™ targets BLA submission in 2027. Cash position at end of Q2 2026 was 49.5 MSEK, with continued focus on biosimilar development and commercialization.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.